



---

**TTK Healthcare**  
**LIMITED**

---

TTKH:SECL:GJ:284:18

October 31, 2018

National Stock Exchange of India Limited (NSE)  
Exchange Plaza  
Bandra Kurla Complex  
Bandra East  
Mumbai 400 051

---

**Scrip Code : TTKHLTCARE**

---

Dear Sirs,

**Re : Unaudited Financial Results along with Limited Review Report for the  
Quarter and Half-Year ended 30<sup>th</sup> September, 2018 (Standalone)**

---

We are forwarding herewith the Unaudited Financial Results along with the Limited Review Report from the Statutory Auditors of the Company, for the Quarter and Half-Year ended 30<sup>th</sup> September, 2018, duly reviewed by the Audit Committee and approved by the Board of Directors of the Company at their Meeting held today.

Kindly take the above documents on record.

Thanking you

Yours faithfully  
For TTK Healthcare Limited

**(S KALYANARAMAN)**  
*Director & Wholetime Secretary*

Encl. : a/a



# TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086  
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED 30TH SEPTEMBER, 2018 (STANDALONE)

[Prepared in compliance with the Indian Accounting Standards (Ind AS)]

| Sl. No. | Particulars                                                                                                                              | For the Quarter ended |                  |                  | For the Half year ended |                  | (Rs. in lakhs)     |
|---------|------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------------|------------------|-------------------------|------------------|--------------------|
|         |                                                                                                                                          | (30/09/2018)          | (30/06/2018)     | (30/09/2017)     | (30/09/2018)            | (30/09/2017)     | For the Year ended |
|         |                                                                                                                                          | Unaudited             | Unaudited        | Unaudited        | Unaudited               | Unaudited        | Audited            |
| I.      | Revenue from Operations                                                                                                                  | 16,609.78             | 17,313.10        | 15,555.02        | 33,922.88               | 28,551.55        | 57,754.65          |
| II.     | Other Income                                                                                                                             | 189.77                | 183.35           | 172.93           | 373.12                  | 346.76           | 757.47             |
| III.    | <b>Total Income (I + II)</b>                                                                                                             | <b>16,799.55</b>      | <b>17,496.45</b> | <b>15,727.95</b> | <b>34,296.00</b>        | <b>28,898.31</b> | <b>58,512.12</b>   |
| IV.     | Expenses                                                                                                                                 |                       |                  |                  |                         |                  |                    |
|         | (a) Cost of materials consumed                                                                                                           | 2,790.63              | 2,289.14         | 2,130.67         | 5,079.77                | 3,934.00         | 8,713.56           |
|         | (b) Purchase of Stock-in-trade                                                                                                           | 4,560.03              | 4,643.67         | 3,580.91         | 9,203.70                | 7,774.70         | 15,437.58          |
|         | (c) Changes in inventories of Finished Goods, Work-in-progress and Stock-in-trade                                                        | -467.43               | 125.76           | 687.06           | (341.67)                | 129.79           | 8.20               |
|         | (d) Employee benefits expense                                                                                                            | 3,320.42              | 3,395.71         | 3,066.86         | 6,716.13                | 6,219.31         | 12,011.55          |
|         | (e) Finance Costs                                                                                                                        | 94.14                 | 104.93           | 119.22           | 199.07                  | 234.30           | 472.93             |
|         | (f) Depreciation and Amortization Expense                                                                                                | 347.66                | 363.82           | 390.63           | 711.48                  | 784.78           | 1,524.22           |
|         | (g) Other Expenses                                                                                                                       | 5,057.46              | 5,277.93         | 4,346.24         | 10,335.39               | 9,742.44         | 17,329.37          |
|         | <b>Total Expenses (IV)</b>                                                                                                               | <b>15,702.91</b>      | <b>16,200.96</b> | <b>14,321.59</b> | <b>31,903.87</b>        | <b>28,819.32</b> | <b>55,497.41</b>   |
| V.      | <b>Profit / (Loss) before Exceptional Items and Tax (III - IV)</b>                                                                       | <b>1,096.64</b>       | <b>1,295.49</b>  | <b>1,406.36</b>  | <b>2,392.13</b>         | <b>78.99</b>     | <b>3,014.71</b>    |
| VI.     | Exceptional Items                                                                                                                        | -                     | -                | -                | -                       | -                | -                  |
| VII.    | <b>Profit / (Loss) before Tax (V - VI)</b>                                                                                               | <b>1,096.64</b>       | <b>1,295.49</b>  | <b>1,406.36</b>  | <b>2,392.13</b>         | <b>78.99</b>     | <b>3,014.71</b>    |
| VIII.   | Tax Expense:                                                                                                                             |                       |                  |                  |                         |                  |                    |
|         | (1) Current Tax                                                                                                                          | 400.00                | 490.00           | 304.00           | 890.00                  | 304.00           | 1,125.00           |
|         | (2) Deferred Tax                                                                                                                         | 30.80                 | 17.69            | (17.55)          | 48.49                   | (17.55)          | 73.18              |
| IX.     | <b>Profit / (Loss) for the period from Continuing Operations (VII - VIII)</b>                                                            | <b>665.84</b>         | <b>787.80</b>    | <b>1,119.91</b>  | <b>1,453.64</b>         | <b>(207.46)</b>  | <b>1,816.53</b>    |
| X.      | Profit / (Loss) from Discontinued Operations                                                                                             | -                     | -                | -                | -                       | -                | -                  |
| XI.     | Tax Expense of Discontinued Operations                                                                                                   | -                     | -                | -                | -                       | -                | -                  |
| XII.    | Profit / (Loss) from Discontinued Operations (after tax) (X - XI)                                                                        | -                     | -                | -                | -                       | -                | -                  |
| XIII.   | <b>Profit / (Loss) for the period (IX + XII)</b>                                                                                         | <b>665.84</b>         | <b>787.80</b>    | <b>1,119.91</b>  | <b>1,453.64</b>         | <b>(207.46)</b>  | <b>1,816.53</b>    |
| XIV.    | <b>Other Comprehensive Income:</b>                                                                                                       |                       |                  |                  |                         |                  |                    |
|         | (A) (i) Items that will not be reclassified subsequently to profit or loss                                                               | 86.66                 | (58.48)          | (54.69)          | 28.18                   | 53.82            | 104.65             |
|         | (ii) Income tax relating to items that will not be reclassified to profit or loss                                                        | -                     | -                | -                | -                       | -                | (21.22)            |
|         | (B) (i) Items that will be reclassified to profit or loss                                                                                | -                     | -                | -                | -                       | -                | -                  |
|         | (ii) Income tax relating to items that will be reclassified to profit or loss                                                            | -                     | -                | -                | -                       | -                | -                  |
| XV.     | <b>Total Comprehensive Income for the period (XIII + XIV) [Comprising Profit / (Loss) and Other Comprehensive Income for the period]</b> | <b>752.50</b>         | <b>729.32</b>    | <b>1,065.22</b>  | <b>1,481.82</b>         | <b>(153.64)</b>  | <b>1,899.96</b>    |
|         | Paid-up Equity Share Capital (Face Value Rs.10 per share)                                                                                | 1,413.03              | 1,413.03         | 1,413.03         | 1,413.03                | 1,413.03         | 1,413.03           |
|         | Other Equity as per Balance Sheet of previous accounting year                                                                            | -                     | -                | -                | -                       | -                | 21,884.41          |
| XVI.    | <b>Earnings per Equity Share (For Continuing Operations):</b>                                                                            |                       |                  |                  |                         |                  |                    |
|         | (1) Basic (in Rs.)                                                                                                                       | 4.71                  | 5.58             | 7.93             | 10.29                   | (1.47)           | 12.86              |
|         | (2) Diluted (in Rs.)                                                                                                                     | 4.71                  | 5.58             | 7.93             | 10.29                   | (1.47)           | 12.86              |
| XVII.   | <b>Earnings per Equity Share (For Discontinued Operations):</b>                                                                          |                       |                  |                  |                         |                  |                    |
|         | (1) Basic (in Rs.)                                                                                                                       | -                     | -                | -                | -                       | -                | -                  |
|         | (2) Diluted (in Rs.)                                                                                                                     | -                     | -                | -                | -                       | -                | -                  |
| XVIII.  | <b>Earnings per Equity Share (For Discontinued and Continuing Operations):</b>                                                           |                       |                  |                  |                         |                  |                    |
|         | (1) Basic (in Rs.)                                                                                                                       | 4.71                  | 5.58             | 7.93             | 10.29                   | (1.47)           | 12.86              |
|         | (2) Diluted (in Rs.)                                                                                                                     | 4.71                  | 5.58             | 7.93             | 10.29                   | (1.47)           | 12.86              |

**Notes:**

- (1) The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 31st October, 2018 at Chennai.
- (2) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (3) As the Hon'ble National Company Law Tribunal (NCLT) Order was passed on 15th December, 2017, the figures presented in the previous year for the period ended 30th September, 2017 did not include the figures related to TTK Protective Devices Limited and its Wholly Owned Subsidiary TSL Techno Services Limited which merged with the Company and the Paid-up Share Capital was shown as Rs.776.60 lakhs before allotment of shares to the Shareholders of TTK Protective Devices Limited. The previous year figures presented herein include the figures related to TTK Protective Devices Limited and its Wholly Owned Subsidiary TSL Techno Services Limited and the Share Capital and the Earnings per share shown are after giving effect to shares issued post September 30, 2017.
- (4) The Tax Expense for the Quarter and Half-Year ended 30th September, 2017 had been retained by the Company as originally provided in the books, prior to merger.
- (5) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's presentation.
- (6) This Statement is also available on the website of BSE Limited ([www.bseindia.com](http://www.bseindia.com)) and National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)) and also on the website of the Company ([www.ttkhealthcare.com](http://www.ttkhealthcare.com)).
- (7) **Statement of Assets and Liabilities as at 30th September, 2018:**

| (Rs. in lakhs) |                                           |                  |                  |
|----------------|-------------------------------------------|------------------|------------------|
| Sl. No.        | Particulars                               | As on 30/09/2018 | As on 31/03/2018 |
| (A)            | <b>ASSETS:</b>                            |                  |                  |
| I              | <b>Non-Current Assets:</b>                |                  |                  |
| (a)            | Property, Plant and Equipment             | 10,314.31        | 10,894.98        |
| (b)            | Capital Work-in-Progress                  | 250.52           | 79.16            |
| (c)            | Other Intangible Assets                   | 60.10            | 57.61            |
| (d)            | Financial Assets                          |                  |                  |
|                | (i) Investments                           | 954.07           | 925.89           |
|                | (ii) Others Financial Assests             | 215.06           | 204.42           |
| (e)            | Non-current Tax Assets (Net)              | 2,012.63         | 2,109.18         |
| (f)            | Deferred Tax Assets (Net)                 | 406.64           | 455.13           |
| (g)            | Other Non-current Assets                  | 433.07           | 441.31           |
|                | <b>Total Non-Current Assets</b>           | <b>14,646.40</b> | <b>15,167.68</b> |
| II             | <b>Current Assets:</b>                    |                  |                  |
| (a)            | Inventories                               | 5,491.51         | 5,289.51         |
| (b)            | Financial Assets                          |                  |                  |
|                | (i) Other Investments                     | -                | -                |
|                | (ii) Trade Receivables                    | 8,379.90         | 5,533.71         |
|                | (iii) Cash and Cash Equivalents           | 1,363.29         | 1,492.32         |
|                | (iv) Bank balances other than (iii) above | 10,496.29        | 12,095.27        |
|                | (v) Other Financial Assets                | 709.16           | 567.17           |
| (c)            | Other Current Assets                      | 609.20           | 583.39           |
|                | <b>Total Current Assets</b>               | <b>27,049.35</b> | <b>25,561.37</b> |
|                | <b>TOTAL ASSETS</b>                       | <b>41,695.75</b> | <b>40,729.05</b> |

|     |                                                     |                  |                  |  |
|-----|-----------------------------------------------------|------------------|------------------|--|
| (B) | <b>EQUITY AND LIABILITIES:</b>                      |                  |                  |  |
|     | <b>(1) Equity</b>                                   |                  |                  |  |
|     | (a) Equity Share Capital                            | 1,413.03         | 1,413.03         |  |
|     | (b) Other Equity                                    | 22,514.50        | 21,884.41        |  |
|     | <b>Equity attributable to owners of the Company</b> | <b>23,927.53</b> | <b>23,297.44</b> |  |
|     | <b>Total Equity</b>                                 | <b>23,927.53</b> | <b>23,297.44</b> |  |
|     | <b>(2) Liabilities</b>                              |                  |                  |  |
|     | <b>Non-current Liabilities:</b>                     |                  |                  |  |
|     | (a) Financial Liabilities                           |                  |                  |  |
|     | (i) Borrowings                                      | 48.02            | 65.93            |  |
|     | (b) Deferred Tax Liabilities (Net)                  | 524.04           | 613.38           |  |
|     | <b>Total Non-current Liabilities</b>                | <b>572.06</b>    | <b>679.31</b>    |  |
|     | <b>Current Liabilities:</b>                         |                  |                  |  |
|     | (a) Financial Liabilities                           |                  |                  |  |
|     | (i) Borrowings                                      | 2,889.58         | 4,639.01         |  |
|     | (ii) Trade Payables                                 |                  |                  |  |
|     | * Micro and Small Enterprises Payables              | -                | -                |  |
|     | * Other Payables                                    | 10,446.50        | 8,632.87         |  |
|     | (iii) Other Financial Liabilities                   | 2,612.17         | 2,771.93         |  |
|     | (b) Provisions                                      | 137.39           | 127.01           |  |
|     | (c) Current Tax Liabilities (Net)                   | 440.00           | 203.64           |  |
|     | (d) Other Current Liabilities                       | 670.52           | 377.84           |  |
|     | <b>Total Current Liabilities</b>                    | <b>17,196.16</b> | <b>16,752.30</b> |  |
|     | <b>TOTAL LIABILITIES</b>                            | <b>17,768.22</b> | <b>17,431.61</b> |  |
|     | <b>TOTAL EQUITY AND LIABILITIES</b>                 | <b>41,695.75</b> | <b>40,729.05</b> |  |

Place: Chennai  
Date: October 31, 2018

For TTK Healthcare Limited

T T RAGHUNATHAN  
EXECUTIVE VICE CHAIRMAN



# TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086  
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

## SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER AND HALF-YEAR ENDED 30TH SEPTEMBER, 2018

| Sl. No. | Particulars                                                                               | (Rs. in lakhs)          |                         |                         |                         |                         |                         |
|---------|-------------------------------------------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|         |                                                                                           | For the Quarter ended   |                         |                         | For the Half year ended |                         | For the Year ended      |
|         |                                                                                           | (30/09/2018)            | (30/06/2018)            | (30/09/2017)            | (30/09/2018)            | (30/09/2017)            | (31/03/2018)            |
|         |                                                                                           | Unaudited               | Unaudited               | Unaudited               | Unaudited               | Unaudited               | Audited                 |
| 1.      | <b>Segment Revenue: (Sales and Other Operating Income)</b>                                |                         |                         |                         |                         |                         |                         |
| (a)     | Pharmaceuticals                                                                           | 5,916.44                | 5,553.63                | 5,801.42                | 11,470.07               | 9,321.85                | 19,233.47               |
| (b)     | Consumer Products                                                                         | 4,708.29                | 6,259.00                | 4,815.24                | 10,967.29               | 10,297.11               | 18,429.11               |
| (c)     | Medical Devices                                                                           | 1,038.19                | 1,133.80                | 757.87                  | 2,171.99                | 1,504.29                | 3,265.18                |
| (d)     | Protective Devices                                                                        | 2,937.40                | 2,749.95                | 2,515.24                | 5,687.35                | 3,953.63                | 10,066.98               |
| (e)     | Foods                                                                                     | 1,997.37                | 1,595.53                | 1,655.27                | 3,592.90                | 3,438.68                | 6,701.02                |
| (f)     | Others                                                                                    | 12.09                   | 21.19                   | 9.98                    | 33.28                   | 35.99                   | 58.89                   |
|         | <b>Total</b>                                                                              | <b>16,609.78</b>        | <b>17,313.10</b>        | <b>15,555.02</b>        | <b>33,922.88</b>        | <b>28,551.55</b>        | <b>57,754.65</b>        |
|         | <b>Less : Inter Segment Revenue</b>                                                       | -                       | -                       | -                       | -                       | -                       | -                       |
|         | <b>Net Sales / Income from Operations</b>                                                 | <b>16,609.78</b>        | <b>17,313.10</b>        | <b>15,555.02</b>        | <b>33,922.88</b>        | <b>28,551.55</b>        | <b>57,754.65</b>        |
| 2.      | <b>Segment Results: [Profit (+) / Loss (-) before tax and interest from each segment]</b> |                         |                         |                         |                         |                         |                         |
| (a)     | Pharmaceuticals                                                                           | 732.53                  | 424.02                  | 832.11                  | 1,156.55                | 473.78                  | 1,323.86                |
| (b)     | Consumer Products                                                                         | 821.02                  | 1,130.00                | 627.28                  | 1,951.02                | 987.47                  | 2,871.16                |
| (c)     | Medical Devices                                                                           | 222.80                  | 275.01                  | 146.30                  | 497.81                  | 297.95                  | 765.70                  |
| (d)     | Protective Devices                                                                        | (165.01)                | (5.17)                  | 322.67                  | (170.18)                | (600.77)                | 206.94                  |
| (e)     | Foods                                                                                     | (137.98)                | (177.13)                | (142.59)                | (315.11)                | (338.64)                | (728.67)                |
| (f)     | Others                                                                                    | 5.64                    | 10.68                   | 2.05                    | 16.32                   | 10.47                   | 17.17                   |
|         | <b>Total</b>                                                                              | <b>1,479.00</b>         | <b>1,657.41</b>         | <b>1,787.82</b>         | <b>3,136.41</b>         | <b>830.26</b>           | <b>4,456.16</b>         |
|         | <b>Less : Finance Cost</b>                                                                | <b>94.14</b>            | <b>104.93</b>           | <b>119.22</b>           | <b>199.07</b>           | <b>234.30</b>           | <b>472.93</b>           |
|         | <b>Less : Unallocable Expenses (Net of Unallocable Income)</b>                            | <b>288.22</b>           | <b>256.99</b>           | <b>262.24</b>           | <b>545.21</b>           | <b>516.97</b>           | <b>968.52</b>           |
|         | <b>Total Profit (+) / Loss (-) before tax</b>                                             | <b>1,096.64</b>         | <b>1,295.49</b>         | <b>1,406.36</b>         | <b>2,392.13</b>         | <b>78.99</b>            | <b>3,014.71</b>         |
|         |                                                                                           | <b>As on 30/09/2018</b> | <b>As on 30/06/2018</b> | <b>As on 30/09/2017</b> | <b>As on 30/09/2018</b> | <b>As on 30/09/2017</b> | <b>As on 31/03/2018</b> |
| 3.      | <b>Segment Assets</b>                                                                     |                         |                         |                         |                         |                         |                         |
| (a)     | Pharmaceuticals                                                                           | 5,635.26                | 5,050.10                | 5,068.48                | 5,635.26                | 5,068.48                | 4,356.87                |
| (b)     | Consumer Products                                                                         | 3,335.11                | 3,498.91                | 3,188.06                | 3,335.11                | 3,188.06                | 2,603.78                |
| (c)     | Medical Devices                                                                           | 3,879.95                | 3,638.30                | 2,869.23                | 3,879.95                | 2,869.23                | 3,061.00                |
| (d)     | Protective Devices                                                                        | 8,666.24                | 8,961.40                | 10,831.80               | 8,666.24                | 10,831.80               | 11,190.03               |
| (e)     | Foods                                                                                     | 9,645.43                | 9,739.10                | 10,147.48               | 9,645.43                | 10,147.48               | 9,815.26                |
| (f)     | Others                                                                                    | 93.31                   | 90.60                   | 80.35                   | 93.31                   | 80.35                   | 75.44                   |
|         | <b>Total</b>                                                                              | <b>31,255.30</b>        | <b>30,978.41</b>        | <b>32,185.40</b>        | <b>31,255.30</b>        | <b>32,185.40</b>        | <b>31,102.38</b>        |
|         | Unallocated                                                                               | 13,800.95               | 13,491.78               | 11,698.98               | 13,800.95               | 11,698.98               | 12,166.78               |
|         | <b>Total Assets</b>                                                                       | <b>45,056.25</b>        | <b>44,470.19</b>        | <b>43,884.38</b>        | <b>45,056.25</b>        | <b>43,884.38</b>        | <b>43,269.16</b>        |
| 4.      | <b>Segment Liabilities</b>                                                                |                         |                         |                         |                         |                         |                         |
| (a)     | Pharmaceuticals                                                                           | 5,006.86                | 4,573.01                | 4,485.65                | 5,006.86                | 4,485.65                | 3,829.48                |
| (b)     | Consumer Products                                                                         | 4,999.14                | 5,263.48                | 5,092.96                | 4,999.14                | 5,092.96                | 4,247.11                |
| (c)     | Medical Devices                                                                           | 919.14                  | 958.71                  | 1,048.98                | 919.14                  | 1,048.98                | 769.33                  |
| (d)     | Protective Devices                                                                        | 2,245.02                | 2,275.34                | 2,679.37                | 2,245.02                | 2,679.37                | 2,531.04                |
| (e)     | Foods                                                                                     | 1,072.35                | 761.19                  | 965.18                  | 1,072.35                | 965.18                  | 867.26                  |
| (f)     | Others                                                                                    | 137.43                  | 140.38                  | 138.41                  | 137.43                  | 138.41                  | 136.15                  |
|         | <b>Total</b>                                                                              | <b>14,379.94</b>        | <b>13,972.11</b>        | <b>14,410.55</b>        | <b>14,379.94</b>        | <b>14,410.55</b>        | <b>12,380.37</b>        |
|         | Unallocated                                                                               | 5,223.37                | 4,823.37                | 4,183.92                | 5,223.37                | 4,183.92                | 4,333.36                |
|         | <b>Total Liabilities</b>                                                                  | <b>19,603.31</b>        | <b>18,795.48</b>        | <b>18,594.47</b>        | <b>19,603.31</b>        | <b>18,594.47</b>        | <b>16,713.73</b>        |

**Notes:**

1. Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) considering the organisation structure and the differential risks and returns of these segments.
2. Details of products included in each of the Segments are as below :
  - ❖ Pharmaceuticals include products for both Human and Veterinary use.
  - ❖ Consumer Products comprise marketing and distribution of Woodward's Griewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Freshners, etc., (Own Brands).
  - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
  - ❖ Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products.
  - ❖ Foods comprise manufacturing and marketing of Food Products.
  - ❖ "Others" include Printing and Publishing of Maps and Atlases.
3. The segment-wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
4. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED



Place: Chennai  
Date: October 31, 2018

T T RAGHUNATHAN  
EXECUTIVE VICE CHAIRMAN

**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086

CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com


**EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED 30TH SEPTEMBER, 2018 (STANDALONE)**

| (Rs. in lakhs) |                                                                                                                                              |                       |              |              |                         |              |                    |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|--------------|--------------|-------------------------|--------------|--------------------|
| Sl. No.        | Particulars                                                                                                                                  | For the Quarter ended |              |              | For the Half year ended |              | For the Year ended |
|                |                                                                                                                                              | (30/09/2018)          | (30/06/2018) | (30/09/2017) | (30/09/2018)            | (30/09/2017) | (31/03/2018)       |
|                |                                                                                                                                              | Unaudited             | Unaudited    | Unaudited    | Unaudited               | Unaudited    | Audited            |
| 1.             | Total income from Operations                                                                                                                 | 16,609.78             | 17,313.10    | 15,555.02    | 33,922.88               | 28,551.55    | 57,754.65          |
| 2.             | Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)                                                    | 1,096.64              | 1,295.49     | 1,406.36     | 2,392.13                | 78.99        | 3,014.71           |
| 3.             | Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items)                                               | 1,096.64              | 1,295.49     | 1,406.36     | 2,392.13                | 78.99        | 3,014.71           |
| 4.             | Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items)                                                | 665.84                | 787.80       | 1,119.91     | 1,453.64                | (207.46)     | 1,816.53           |
| 5.             | Total comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)] | 752.50                | 729.32       | 1,065.22     | 1,481.82                | (153.64)     | 1,899.96           |
| 6.             | Equity Share Capital (Face Value of Rs.10/- per share)                                                                                       | 1,413.03              | 1,413.03     | 1,413.03     | 1,413.03                | 1,413.03     | 1,413.03           |
| 7.             | Other Equity as per the Balance Sheet of previous accounting year                                                                            |                       |              |              |                         |              | 21,884.41          |
| 8.             | Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)                                                            |                       |              |              |                         |              |                    |
| (a)            | Basic (in Rs.)                                                                                                                               | 4.71                  | 5.58         | 7.93         | 10.29                   | (1.47)       | 12.86              |
| (b)            | Diluted (in Rs.)                                                                                                                             | 4.71                  | 5.58         | 7.93         | 10.29                   | (1.47)       | 12.86              |

**Notes:**

- The above is an extract of the detailed Statement of Unaudited Financial Results for the Second Quarter ended 30th September, 2018, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The full financial results for the Second Quarter ended 30th September, 2018 are available on the website of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).
- These financial results have been reviewed by the Audit Committee of the Company and approved by the Board of Directors at their Meeting held on 31st October, 2018 at Chennai.
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- As the Hon'ble National Company Law Tribunal (NCLT) Order was passed on 15th December, 2017, the figures presented in the previous year for the period ended 30th September, 2017 did not include the figures related to TTK Protective Devices Limited and its Wholly Owned Subsidiary TSL Techno Services Limited which merged with the Company and the Paid-up Share Capital was shown as Rs.776.60 lakhs before allotment of shares to the Shareholders of TTK Protective Devices Limited. The previous year figures presented herein include the figures related to TTK Protective Devices Limited and its Wholly Owned Subsidiary TSL Techno Services Limited and the Share Capital and the Earnings per share shown are after giving effect to shares issued post September 30, 2017.
- The Tax Expense for the Quarter and Half-Year ended 30th September, 2017 had been retained by the Company as originally provided in the books, prior to merger.
- The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's presentation.

For TTK HEALTHCARE LIMITED

  
**T T RAGHUNATHAN**  
**EXECUTIVE VICE CHAIRMAN**
**Place: Chennai**  
**Date: October 31, 2018**

**Independent Auditor's Review Report on review of Interim financial results**

**To the Board of Directors of TTK Healthcare Limited**

We have reviewed the Unaudited financial results of TTK Healthcare Limited ("the Company") for the quarter and half year ended 30<sup>th</sup> September 2018 which are included in the accompanying 'Financial Results for the quarter and half year ended 30<sup>th</sup> September 2018 together with the notes thereon ("the Statement")'. The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016 which has been initialed by us for identification purposes.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

**Conclusion:**

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Other Matters:**

Figures for the quarter and half year ended 30<sup>th</sup> September 2017 include management certified figures of TTK Protective Devices Limited and TSL Techno Services Limited (together called TTKPDL), which Companies got merged with TTK Healthcare Limited during the year 2017-18 pursuant to Court order received in December 2017.

Our conclusion is not modified in respect of the said matter.

For PKF Sridhar & Santhanam LLP

Chartered Accountants

Firm's Registration No. 003990S/S200018

S. Rajeshwari

Partner

Membership No. 024105

Place: Chennai

Date: 31<sup>st</sup> October 2018

